Canaccord Genuity Reiterates Buy on Zevra Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni has reiterated a 'Buy' rating on Zevra Therapeutics (NASDAQ:ZVRA) and maintained a $20 price target.
September 01, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has reiterated a 'Buy' rating on Zevra Therapeutics and maintained a $20 price target.
The reiteration of a 'Buy' rating by Canaccord Genuity, a reputable financial services firm, is a positive signal for Zevra Therapeutics. The maintained price target of $20 also indicates the firm's continued confidence in the stock's potential. This could potentially lead to increased investor confidence and a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100